Oglemilast, formerly known as GRC 3886, is a potent and selective PDE4 inhibitor ( 2.5 nM (PDE4B) and 1.7 nM (PDE4D)). Oglemilast was a drug under development to treat chronic obstructive pulmonary disorder (COPD)—a lung disease—and asthma. In 2009, Phase IIb trials was failed. References: Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol. 2008 Oct;155(3):288-90. doi: 10.1038/bjp.2008.297. Epub 2008 Jul 28. PubMed PMID: 18660832; PubMed Central PMCID: PMC2567889.

纯度：≥98%

CAS：778576-62-8